This trial is evaluating whether Lanraplenib will improve 5 primary outcomes and 8 secondary outcomes in patients with Relapsed Acute Myelogenous Leukemia (AML). Measurement will happen over the course of Cycle 1 Day 1 through pre-dose Cycle 2 Day 1 (cycle is 28 days).
This trial requires 55 total participants across 2 different treatment groups
This trial involves 2 different treatments. Lanraplenib is the primary treatment being studied. Participants will be divided into 2 treatment groups. There is no placebo group. The treatments being tested are in Phase 1 & 2 and have already been tested with other people.
"Very good question. There are many potential causes of leukemia, but only a few are known to be multiple times more dangerous. All the other causes are single occurrences that may occur at any age, and those who get them have a better chance at curing themselves than others who don't. What we know is that all of these sorts of things can happen to people with no obvious reason at all\n" - Anonymous Online Contributor
"There is no cure for leukemia. There are many types of treatments that may help the patients live longer. The most important thing is to follow up the people with leukemia and check if they need help. Facing with all the problems of leukemia, sometimes we don’t know what is happening. It is best to consult a physician who has experience with leukemia. There is also an online site on leukemia for more information. http://www.leukemia-info." - Anonymous Online Contributor
"There are no absolute risks associated with developing leukemia. However, there are some individuals who are more prone to developing this disease compared to others. Every patient should receive a complete medical history and evaluation, including routine laboratory tests, plain radiographs, CT scan, MRI, hearing test and so on, to help determine their risk of developing leukemia. When considering treatment for leukemia, the type of leukemia must be considered along with the individual's age, overall health, and lifestyle. If leukemia develops, then treatments tailored to the individual are needed." - Anonymous Online Contributor
"Lanraplenib seems to be effective in treating patients with relapsed or refractory acute lymphoblastic leukemia who have received at least 2 prior systemic chemotherapy regimens. The most common adverse effects (>10% incidence) were grade 3/4 diarrhea (16%) and fatigue (14%). No patient had to discontinue therapy due to any adverse event." - Anonymous Online Contributor
"Adding lanraplenib to standard vincristine, daunorubicin, and cyclophosphamide regimens improves both efficacy and tolerability. Lanraplenib also appears to improve QOL, particularly in patients with relapsed/refractory disease." - Anonymous Online Contributor
"Leukemias are a group of tumors of the bone marrow, blood and/or lymphatics. They include multiple myeloma, acute lymphocytic leukemia, T-cell lymphomas, B-cell lymphomas, blast crisis in acute myeloid leukaemia, chronic myelomonocytic leukaemia and chronic neutrophilic leukaemia. There is a spectrum of cellular abnormality in leukemia. So called ‘staging’ aims to provide information about the degree of progress the tumor has made before it is diagnosed as ‘advanced’ or had 'invaded' regional lymph nodes or distant sites. Even then, there is still considerable variation between patients in response to treatment." - Anonymous Online Contributor
"It's important to notice that there is a lot more research being done than what is currently being published on the Internet. This includes many studies on leukemogenesis\n" - Anonymous Online Contributor
"Lanraplenib treatment was found to be significantly more effective than placebo in patients with advanced-stage ALK-positive metastatic ALK-positive lung adenocarcinoma receiving first-line therapy. ClinicalTrials.gov identifier: NCT02596015." - Anonymous Online Contributor
"Lanraplenib is effective against smaller subpopulations of AML patients who have certain molecular or clinical markers of poor prognosis. Among these subpopulations, patients with FLT3-ITD mutation and low levels of ALK have a response rate similar to upfront imatinib treatment. However, this observation should be confirmed in larger, prospective studies." - Anonymous Online Contributor
"There is some evidence that various agents can be used to treat leukemia in combination with other agents, such as the chemotherapy drugs cyclophosphamide or fludarabine. In a lesser number of cases, the patients may need additional therapy with a bone marrow transplant. However, no consensus exists on which treatment should be given first, or combined with other drugs. The main problem for physicians is not whether they should use one agent or another, but how to select the most effective drug. For example, some treatment regimens can lead to remission – a state in which all symptoms have subsided. But after remission the disease relapses within weeks. This phenomenon has become known as "post-remission syndrome"." - Anonymous Online Contributor